

学 会 等 発 表 実 績

委託業務題目「予後不良の神経腫瘍に対する標準治療の確立と希少癌組織のバイオバンクを目的とした多施設共同研究

機関名 国立がん研究センター

1. 学会等における口頭・ポスター発表

発表した成果（発表題目、口頭・ポスター発表の別）	発表者氏名	発表した場所（学会等名）	発表した時期	内 容
脳腫瘍の治療結果を可視化する大規模データの収集・臨床試験の必要性.	成田善孝, 渋井壮一郎	第34回日本脳神経外科コンgres総会	2014	[
残存腫瘍のあるびまん性星細胞腫に対する照射単独治療とテモゾロミド併用放射線療法を比較するランダム化第Ⅲ相試験 (JCOG1303)	成田善孝, 宮北康二, 江場淳, 水澤純基, 福田治彦, 渋井壮一郎, JCOG 脳腫瘍グループ	第73回日本脳神経外科学会学術総会	2014	[
退形成性神経膠腫に対する ACNU 先行再発時テモゾロミド療法を テモゾロミド療法と比較するランダム化第Ⅲ相試験 (JCOG1016)	村垣善浩, 丸山隆志, 隈部俊宏, 成田善孝, 新田雅之, 生田聡子, 永根基雄, 中村英夫, 片山 宏, 水澤純基, 福田治彦, 渋井壮一郎, JCOG 脳腫瘍グループ	第73回日本脳神経外科学会学術総会	2014	[
JCOG 脳腫瘍グループの現状報告	西川亮	第32回日本脳腫瘍学会学術総会	2014	[

2. 学会誌・雑誌等における論文掲載

掲載した論文（発表題目）	発表者氏名	発表した場所（学会誌・雑誌等名）	発表した時期	国 外
IDH1/2 mutation detection in gliomas	Arita H, Narita Y, Yoshida A, Hashimoto N, Yoshimine T, Ichimura K.	Brain tumor pathology	2014	[
Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas	Arita H, Narita Y, Matsushita Y, Fukushima S, Yoshida A, Takami H, Miyakita Y, Ohno M, Shibui S, Ichimura K.	Brain tumor pathology	2014	[
Revisiting TP53 Mutations and Immunohistochemistry-A Comparative Study in 157 Diffuse Gliomas	Takami H, Yoshida A, Narita Y, Fukushima S, Arita H, Matsushita Y, Nakamura T, Ohno M, Miyakita Y, Shibui S, Ichimura K.	Brain Pathol	2014	[
Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.	Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto, K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A.	J Neurosurg	2014	[
Intraoperative cortico-cortical evoked potentials for the evaluation of language function during brain tumor resection: initial experience with 13	Saito T, Tamura M, Muragaki Y, Maruyama T, Kubota Y, Fukuchi S, Nitta M, Chernov M, Okamoto S, Sugiyama K, Kurisu K, Sakai KL, Okada Y, Iseki H.	J Neurosurg	2014	[

cases.				
Perseveration found in a human drawing task: six-fingered hands drawn by patients with right anterior insula and operculum damage.	Niki C, Maruyama T, Muragaki Y, Kumada T.	Behav Neurol.	2014	[
Intracranial germinomas in a father and his son.	Shimizu K, Mineharu Y, Imamura H, Asai K, Imai Y, Ichimura K, Sakai N	Childs Nerv Syst	2014	[
Amplification of 2p as a genomic marker for transformation in lymphoma	Kwiecinska A, Ichimura K, Berglund M, Dinets A, Sulaiman L, Collins VP, Larsson C, Porwit A, Lagercrantz SB	Genes Chromosome Cancer	2014	[
Mutually exclusive mutations of KIT and RAS are associated with KIT mRNA expression and chromosomal instability in primary intracranial pure germinomas	Fukushima S, Otsuka A, Suzuki T, Yanagisawa T, Mishima K, Mukasa A, Saito N, Kumabe T, Kanamori M, Tominaga T, Narita Y, Shibui S, Kato M, Shibata T, Matsutani M, Nishikawa R, Ichimura K	Acta Neuropathol	2014	[
Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.	Quillien V, Lavenu A, Sanson M, Legrain M, Dubus P, Karayan-Tapon L, Mosser J, Ichimura K, Figarella-Branger D	J Neurooncol	2014	[
Practical surgical indicators to identify candidates for radical resection of insulo-opercular gliomas	Kawaguchi T, Kumabe T, Saito R, Kanamori M, Iwasaki M, Yamashita Y, Sonoda Y, Tominaga T	J Neurosurg	2014	[
Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells.	Sato A, Okada M, Shibuya K, Watanabe E, Seino S, Narita Y, Shibui S, Kayama T, Kitanaka C	Stem Cell Res	2014	[
Molecular targeting of neuroblastoma with a novel p16INK4a transporter system	Kawaguchi T, Yoshikawa K, Kawamoto K, Yoshimura K, Oshige H, Asai A	Int J Oncol	2014	[
Tohoku Brain Tumor Study Group: Treatment outcomes in glioblastoma patients aged 76 years or older: a multicenter retrospective cohort study	Uzuka T, Asano K, Sasajima T, Sakurada K, Kumabe T, Beppu T, Ichikawa M, Kitanaka C, Aoki H, Saito K, Ogasawara K, Tominaga T, Mizoi K, Ohkuma H, Fujii Y, Kayama T	J Neurooncol.	2014	[
Estimation of proliferative potentiality of central neurocytoma: correlational analysis of minimum ADC and maximum SUV with MIB-1 labeling index	Sakamoto R, Okada T, Kanagaki M, Yamamoto A, Fushimi Y, Kakigi T, Arakawa Y, Takahashi JC, Mikami Y, Togashi K.	Acta radiologica	2015	[
Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature	Iwadate Y, Suganami A, Ikegami S, Shinozaki N, Matsutani T, Tamura Y, Saeki N, Yamanaka R	J Neurooncol	2014	[
Circulating anti-filamin C autoantibody as a potential serum biomarker for low-grade gliomas	Adachi-Hayama M, Adachi A, Shinozaki N, Matsutani T, Hiwasa T, Takiguchi M, Saeki N, Iwadate Y	BMC Cancer	2014	[
Malignant progression of glioblastoma	Iwadate Y	J Cell Sci Ther	2014	[
Diffusion tensor magnetic resonance imaging-based tractography for glioma surgery. In: Hayat MA, ed. Heidelberg:New York: London	Ohue S, Kohno S, Kumon Y, Ohnishi T.	Springer	2014	[

Different spatial distribution between GCB and non-GCB primary central nervous system lymphoma revealed by MR group analysis	Kinoshita M, Sasayama T, Narita Y, Yamashita F, Kawaguchi A, Chiba Y, Kagawa N, Tanaka K, Kohmura E, Arita H, Okita Y, Ohno M, Miyakita Y, Shibui S, Hashimoto N, Yoshimine T	Neuro-oncology	2014	[
Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis.	Kijima N, Hosen N, Kagawa N, Hashimoto N, Kinoshita M, Oji Y, Sugiyama H, Yoshimine T	Anticancer Res	2014	[
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy	Motegi H, Kamoshima Y, Terasaka S, Kobayashi H, Yamaguchi S, Tanino M, Murata J, Houkin K.	Brain Tumor Pathol	2014	[
Combined use of 18 F-FDG PET and corticosteroid for diagnosis of deep-seated primary central nervous system lymphoma without histopathological confirmation.	Yamaguchi S, Hirata K, Kaneko S, Kobayashi H, Shiga T, Kobayashi K, Onimaru R, Shirato H, Tamaki N, Terasaka S, Houkin K.	Acta Neurochir (Wien)	2014	[
Radiological features of supratentorial gliomas are associated with their genetic aberrations.	Nishiyama Y, Sasaki H, Nagahisa S, Adachi K, Hayashi T, Yoshida K, Kawase T, Hattori N, Murayama K, Abe M, Hasegawa M, Katada K, Hirose Y	Neurosurgical Review	2014	[
Intraparenchymal, primary central nervous system lymphoma of low-grade B cell malignancy: a case report with review of the literature on therapeutic consideration.	Tomio R, Sasaki H, Hirose S, Shimizu T, Koda Y, Ohno M, Narita Y, Shibao S, Yoshida K	Int Canc Conf J	2014	[
Intraoperative cortico-cortical evoked potentials for the evaluation of language function during brain tumor resection: initial experience with 13 cases	Saito T, Muragaki Y, Sugiyama K, Kubota Y, Fukuchi S, Nitta M, Chernov M, Okamoto S, Sugiyama K, Kurisu K, Sakai KL, Okada Y, Iseki H.	J Neurosurg	2014	[
NPC-08 study group. A multicenter phase I/II study of the BCNU implant (Gliadel®) Wafer for Japanese patients with malignant gliomas.	Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, Kawabata N, Mishima K, Adachi J, Kurisu K, Yamasaki F, Tominaga T, Kumabe T, Ueki K, Higuchi F, Yamamoto T, Ishikawa E, Takeshima H, Yamashita S, Arita K, Hirano H, Yamada S, Matsutani M	Neurol Med Chir (Tokyo).	2014	[
Diagnostic yield and morbidity by neuronavigation-guided frameless stereotactic biopsy using magnetic resonance imaging and by frame-based computed tomography-guided stereotactic biopsy	Nishihara M, Takeda N, Sasayama T, Harada T, Kidoguchi K, Tatsumi S, Tanaka K, Kohmura E.	Surg Neurol Int	2014	[
Malignant clinical features of anaplastic gliomas without IDH mutation	Shibahara I, Sonoda Y, Shoji T, Kanamori M, Saito R, Inoue T, Kawaguchi T, Yamashita Y, Watanabe T, Kumabe T, Watanabe M, Suzuki H, Tominaga T	Neuro Oncol	2015	[

Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients	Kanamori M, Higa T, Sonoda Y, Murakami S, Dodo M, Kitamura H, Taguchi K, Shibata T, Watanabe M, Suzuki H, Shibahara I, Saito R, Yamashita Y, Kumabe T, Yamamoto M, Motohashi H, Tominaga T	Neuro Oncol	2015	[
Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme	Kawasoe T, Takeshima H, Yamashita S, Mizuguchi S, Fukushima T, Yokogami K, and Yamasaki K	J Neurosurg	2015	[
Proposed strategy for the use of high-dose chemotherapy with stem cell rescue and intrathecal topotecan without whole-brain irradiation for infantile classic medulloblastoma	Yamada A, Moritake H, Kamimura S, Yamashita S, Takeshima H, Nuno H	Pediatr Blood Cancer.	2014	[
Case of primary diffuse leptomeningeal gliomatosis	Yamasaki K, Yokogami K, Ohta H, Yamashita S, Uehara H, Sato Y, Takeshima H.	Brain Tumor Pathol	2014	[
The perivascular microenvironment in primary central nervous system lymphomas	Sugita Y, Terasaki M, Nakashima S, Ohshima K, Morioka M, Abe H	Brain Tumor Pathol	2015	[
Cancer specific health-related quality of life in children with brain tumors	Sato I, Higuchi A, Yanagisawa T, Mukasa A, Ida K, Sawamura Y, Sugiyama K, Saito N, Kumabe T, Terasaki M, Nishikawa R, Ishuda Y, Kamibeppu K	Qual Life Res.	2014	[
Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients	Akiyama Y, Komiyama M, Miyata H, Yagoto M, Ahizawa T, Iizuka A, Oshita C, Kume A, Nogami M, Ito I, Watanabe R, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Yamaguchi K.	Oncol Rep	2014	[
Metastatic skull tumours: Diagnosis and management	Mitsuya K and Nakasu Y.	EANO Magazine	2014	[
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.	Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, Kim SH, Minata M, Nakano I, Grandis JR, McLendon RE, Bigner DD, Lin HK, Furnari FB, Cavenee WK, Hu B, Yan H, Cheng SY.	J Clin Invest	2014	[
Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab	Nagane M, Kobayashi K, Tanaka M, Tsuchiya K, Shishido-Hara Y, Shimizu S, Shiokawa Y.	Int J Clin Oncol	2014	[
Antitumor effect of fibrin glue containing temozolomide against malignant glioma	Anai S, Hide T, Takezaki T, Kuroda J, Shinojima N, Makino K, Nakamura H, Yano S, Kuratsu J.	Cancer Sci	2014	[
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.	Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T.	N Engl J Med	2014	[

Novel somatic and germline mutations in intracranial germ cell tumours.	Wang L, Yamaguchi S, Burstein MD, Terashima K, Chang K, Ng H-K, Nakamura H, He Z, Doddapaneni H, Lewis L, Wang M, Suzuki T, Nishikawa R, Natsume A, Terasaka S, Dauser R, Whitehead W, Adekunle A, Sun J, Qiao Y, Marth G, Muzny DM, Gibbs RA, Leal SM, Wheeler DA, Lau CC.	Nature	2014	[
Wilm's Tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferatuin and apoptosis	Kijima N, Hosen N, Kagawa N, Hashimoto N, Kinoshita M, Oji Y, Sugiyama H, Yoshimine T.	Anticancer Res	2014	[
IDH1/2 mutation detection in gliomas	Arita H, Narita Y, Yoshida A, Hashimoto N, Yoshimine T, Ichimura K.	Brain Tumor Pathol	2014	[
Immunoreactivity of Wnt5a, Fzd2, Fzd6, and Ryk in glioblastoma: evaluative methodology for DAB chromogenic immunostaining	Hirano H, Yonezawa H, Yunoue S, Habu M, Uchida H, Yoshioka T, Kishida S, Kishida M, Oyoshi T, Fujio S, Sugata S, Yamahata H, Hanaya R, Arita K.	Brain Tumor Pathol	2014	[
A multicenter phase I/II study of the BCNU implant (Gliadel®) Wafer for Japanese patients with malignant gliomas	Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, Kawabata N, Mishima K, Adachi J, Kurisu K, Yamasaki F, Tominaga T, Kumabe T, Ueki K, Higuchi F, Yamamoto T, Ishikawa E, Takeshima H, Yamashita S, Arita K, Hirano H, Yamada S, Matsutani M; NPC-08 study group.	Neurol Med Chir (Tokyo).	2014	[
Standardized uptake value in high uptake area on positron emission tomography with 18F-FRP170 as a hypoxic cell tracer correlates with intratumoral oxygen pressure in glioblastoma	Beppu T, Terasaki K, Sasaki T, Fujiwara S, Matsuura H, Ogasawara K, Sera K, Yamada N, Uesugi N, Sugai T, Kudo K, Sasaki M, Ehara S, Iwata R, Takai Y	Mol Imag Biol	2014	[
Intractable yawning associated with mature teratoma of the supramedial cerebellum	Saura H, Beppu T, Matsuura H, Asahi S, Uesugi N, Sasaki M, Ogasawara K	Neurosurg	2014	[
Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma	Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A	J Neurosurg	2014	[
CXCL12 secreted from glioma stem cells regulates their proliferation.	Uemae Y, Ishikawa E, Osuka S, Matsuda M, Sakamoto N, Takano S, Nakai K, Yamamoto T, Matsumura A.	J Neurooncol.	2014	[
Selective accumulation of hematoporphyrin derivative in glioma through proton-coupled folate transporter SLC46A1	Takada T, Tamura M, Yamamoto T, Matsui H, Matsumura A.	J Clin Biochem Nutr.	2014	[
5-Hydroxymethylcytosine Plays a Critical Role in Glioblastomagenesis by Recruiting the CHTOP-Methylosome Complex	Takai H, Masuda K, Sato T, Sakaguchi Y, Suzuki T, Suzuki T, Koyama-Nasu R, Nasu-Nishimura Y, Katou Y, Ogawa H, Morishita Y, Kozuka-Hata H, Oyama M, Todo T, Ino Y, Mukasa A, Saito N, Toyoshima C, Shirahige K, Akiyama T	Cell Rep	2014	[

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.	Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungall AJ, Jones SJ, Hirst M, Marra MA, Saito N, Aburatani H, Mukasa A, Berger MS, Chang SM, Taylor BS, Costello JF.	Science	2014	[
H3F3A K27M mutations in thalamic gliomas from young adult patients	Aihara K, Mukasa A, Gotoh K, Saito K, Nagae G, Tsuji S, Tatsuno K, Yamamoto S, Takayanagi S, Narita Y, Shibui S, Aburatani H, Saito N	Neuro Oncol	2014	[
Efficacy of ribavirin against malignant glioma cell lines	Ogino A, Sano E, Ochiai Y, Yamamuro S, Tashiro S, Yachi K, Ohta T, Fukushima T, Okamoto Y, Tsumoto K, Ueda T, Yoshino A, Katayama Y.	Oncol Lett	2014	[
<sup>62</sup> Cu-Diacetyl Bis (N4-methylthiosemicarbazone) PET in human gliomas:Comparative Study with <sup>18</sup> F-fluorodeoxyglucose and L-Methyl- <sup>11</sup> C-Methionine PET.	Tateishi K, Tateishi U, Nakanowatari S, Ohtake M, Minamimoto R, Suenaga J, Murata H, Kubota K, Inoue T, Kawahara K	AJNR Am J Neuroradiol	2014	[
Radiological features of supratentorial gliomas are associated with their genetic aberrations.	Nishiyama Y, Sasaki H, Nagahisa S, Adachi K, Hayashi T, Yoshida K, Kawase T, Hattori N, Murayama K, Abe M, Hasegawa M, Hirose Y.	Neurosurg Rev	2014	[
Tohoku Brain Tumor Study Group. Treatment outcomes in glioblastoma patients aged 76 years or older: a multicenter retrospective cohort study	Uzuka T, Asano K, Sasajima T, Sakurada K, Kumabe T, Beppu T, Ichikawa M, Kitanaka C, Aoki H, Saito K, Ogasawara K, Tominaga T, Mizoi K, Ohkuma H, Fujii Y, Kayama T	J Neurooncol	2014	[

(注1) 発表者氏名は、連名による発表の場合には、筆頭者を先頭にして全員を記載すること。

(注2) 本様式は excel 形式にて作成し、甲が求める場合は別途電子データを納入すること。